本研究旨在确定4氨基吡啶缓释片(4ＡＰＳＲ)对多发性硬化症(ＭＳ)功能定量测定的影响。方法　10例临床确诊的ＭＳ患者,其中男4,女6例,平均年龄484±67(33～57)岁,平均病程135±91(1～26)年。患者均以肢体无力为主要症状,神经学缺陷稳定至少1个月。凡有各种癫痫样发作病史、不可 The purpose of this study was to determine the effect of 4-aminopyridine sustained-release tablets (4APSR) on the quantitative determination of multiple sclerosis (MS). Methods Ten patients with clinically diagnosed MS, including 4 males and 6 females, with an average age of 484 ± 67 (33-57 years) and an average duration of 135 ± 91 (1-26) years. Patients are limb weakness as the main symptoms, neurological deficits stable at least 1 month. Where there is a history of epileptic seizures, no